• linkedin
  • Increase Font
  • Sharebar

    Mining data for anti-VEGF therapy insights in PCV

    Real-world evidence confirms the benefits of intravitreous ranibizumab (Lucentis, Genentech) for treatment of neovascular age-related macular degeneration (nAMD)—regardless of polypoidal choroidal vasculopathy (PCV) status.

    Seattle—Real-world evidence confirms the benefits of intravitreous ranibizumab (Lucentis, Genentech) for treatment of neovascular age-related macular degeneration (nAMD)—regardless of polypoidal choroidal vasculopathy (PCV) status. That’s according to the findings of a third interim analysis of data collected in the LUMINOUS study.

    Recent: Two genetic discoveries may offer hope for patients with advanced AMD

    The research was presented by Adrian Koh, MD, director, Eye and Retina Surgeons, Camden Medical Centre, Singapore, at ARVO 2016.

    There is limited evidence from randomized, controlled trials on the most efficacious treatment for PCV, which is considered to be a variant or subtype of nAMD, Dr. Koh said.

    Related: Developing cell-based therapies for inherited retinal disease

    “LUMINOUS is the largest observational trial in medical retina and provides the largest dataset for the treatment of PCV patients with ranibizumab in a real-world situation,” Dr. Koh said. “These initial results suggest that patients with nAMD with and without PCV can be treated similarly with ranibizumab.”

    In total, LUMINOUS has recruited 30,514 patients in 43 countries across nearly 500 sites.

    Recent: Pipeline for dry AMD features diverse compounds

    In his presentation, Dr. Koh included data from patients completing 1 year of follow-up. The cohort comprised 1,094 patients with PCV and 16,498 non-PCV patients. The PCV and non-PCV patients were similar at baseline in terms of mean visual acuity (VA) and central retinal thickness (CRT).

    Safety analysis

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';